Comparable detection of large tumor-derived vesicles (oncosomes) by known CTC platforms: potential new analyte for biomarker monitoring?

Home > Science Hub > Comparable detection of large tumor-derived vesicles (oncosomes) by known CTC platforms: potential new analyte for biomarker monitoring?
Back to the list

April 27, 2025

Eszter Papp, Pieter Mestdagh

You might also be interested by

Press Releases

CellCarta and Pillar Biosciences Announce Multi-Year Global Strategic Partnership to Expand Rapid, Decentralized Tumor Profiling for Oncology Clinical Trials

April 7, 2026

More info

News

CellCarta and Lunit Announce Strategic Collaboration to Accelerate AI-Enabled Digital Pathology for Companion Diagnostic Programs

March 30, 2026

More info

News

CellCarta Secures Global Exclusivity for Biofidelity's Aspyre® Lung to Advance Targeted Lung Cancer Testing

March 18, 2026

More info

Posters

Validation of an ultra-sensitive assay for biomarker testing in NSCLC patients as Clinical Trial Assay (CTA)

March 3, 2026

More info